Two men who started taking the antipsychotic drug Risperdal in the 1990s had no way of suspecting its link to excessive breast tissue growth they experienced—until their mothers saw TV commercials discussing the link more than a decade later—attorneys have argued to the Pennsylvania Supreme Court in an effort to expand the statute of limitations for bringing lawsuits over the drug.
Attorneys for plaintiffs Jonathan Saksek and Joshua Winter filed a brief to the Pennsylvania Supreme Court on Wednesday asking the justices to overrule a Superior Court decision that said plaintiffs should have been aware of the connection by 2006.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]